Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis.
Castañón, Eduardo
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. [electronic resource] - Journal of translational medicine Aug 2015 - 257 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1479-5876
10.1186/s12967-015-0622-x doi
Carcinoma, Non-Small-Cell Lung--drug therapy
ErbB Receptors--genetics
Humans
Liver Neoplasms--secondary
Lung Neoplasms--drug therapy
Mutation--genetics
Neoplasm Staging
Prognosis
Survival Analysis
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. [electronic resource] - Journal of translational medicine Aug 2015 - 257 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1479-5876
10.1186/s12967-015-0622-x doi
Carcinoma, Non-Small-Cell Lung--drug therapy
ErbB Receptors--genetics
Humans
Liver Neoplasms--secondary
Lung Neoplasms--drug therapy
Mutation--genetics
Neoplasm Staging
Prognosis
Survival Analysis